Abstract #171 Figure 1 Survival according to different strategies

Introduction/Background To investigate the impact of performing a sentinel lymph node biopsy, a systematic lymphadenectomy, or no lymphadenectomy, in patients with intermediate, intermediate-high- and high-risk endometrial cancer in postoperative diagnosis in early stages.

Methodology Observational, longitudinal, analytical, and retrospective study. A total of 136 patients operated between January 2006 and March 2023, were reviewed. 22 patients with preoperative study of low risk: 6 patients underwent only sentinel lymph node biopsy (SLNB), 5 patients SLNB and pelvic lymphadenectomy (P-LND), and 11 without lymphadenectomy (No-LND). 114 patients with myometrial infiltration >50%, type II or G3 in the preoperative study: 44 patients underwent P-LND and 70 pelvic and paraaortic lymphadenectomy (P-Pa-LND). All patients received the adjuvant treatment decided in the Tumor Committee. Progression-free survival (PFS) and overall survival (OS) were estimated in the four groups.

Results The mean follow-up was 73 months. The mean of removed pelvic lymph nodes was 22 nodes (SD 9.3) and 22.8 (SD 10.3) para-aortic lymph nodes. Pelvic lymph nodes metastasis was observed in 27 cases (24.3%) and 17 cases (24.3%) in para-aortic nodes. In 6 cases para-aortic nodes were positive with negative pelvic lymph nodes (6/50 cases, 12.2%). Considering the P-Pa-LND as standard, no statistically significant differences were found in PFS respected to No-LND (HR: 0.5, 95% CI 0.1–1.7, p=0.27), SLNB (HR: 0.04, 95% CI 0–49.9, p=0.37) and P-LND (HR: 0.65, 95% CI 0.3–1.3, p=0.23); and in OS, respected to No-LND (1.42, 95% CI 0.3–5.3, p=0.6), SLNB (HR: 0.04, p=0.5) and P-LND (HR 1.39, 95% CI 0.5–3.2, p=0.44).

Conclusion It has not been observed that performing different extended lymphadenectomy in intermediate to high-risk endometrial cancer in early stages worsens patient survival.

Disclosures

#183 EXPLORING ENDOMETRIAL CANCER CONVERSATIONS ON INSTAGRAM: INSIGHTS FROM A STUDY BY THE EUROPEAN NETWORK OF YOUNG GYNAECOLOGIC ONCOLOGISTS (ENGYO)

1Raffaella Ergasti*, 2Wasim Ahmed, 3,4Esra Bilir, 5Fabio Martinelli, 6Aleksandra Natalia Strojna, 5Joanna Kaperczyk-Bartnik, 5Sara Nassi, 5Nicolo Bizzanti, 6Martina Aida Angeles, 7Zoia Razumova, 7Charalampos Theofanakis, 7,8Gilberto Morgan, 10Ane Gerda Eriksson. 1UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Policlinico Agostino Gemelli IRCCS, Rome, Italy; 2Stirling University Management School, Stirling, UK; 3Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey; 4Department of Global Health, Koc University Graduate School of Health Sciences, Istanbul, Turkey; 5Department of Obstetrics and Gynecology, Die Klinik in Preetz, Preetz, Germany; 6Department of Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; 7Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, Essen, Germany; 8Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland; 9Department of Gynecology and Tumor Surgery, Charite Comprehensive Cancer Center, Berlin, Germany; 10Gynecologic Oncology Unit, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; 11Department of Obstetrics, Children’s Health, Karolinska Institutet, Stockholm, Sweden; 12Division of Gynecological Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece; 13Department of Medical Oncology, Skane University Hospital, Lund, Sweden; 14OncoAlert Network, Lund, Sweden; 15Department of Gynecologic Oncology, Division of Cancer Medicine, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway

DOES THE COVID-19 VACCINATION INCREASE POSTMENOPAUSAL BLEEDING?

Ester Mirañezk Rovira*, Lucia Pastor-Goutherot, Berta Fabrego, Josep-Maria Sole Sedeno, Gemma Manzebo, Hospital del Mar, Barcelona, Spain

10.1136/ijgc-2023-ESGO.284

10.1136/ijgc-2023-ESGO.285
**Introduction/Background** Social media represents a strong instrument to share and divulge information targeting people of different ages and backgrounds. Little is known regarding how social media may impact patients’ understanding and acceptance of their disease, large-scale screening and health care improvement. Due to the rising incidence of endometrial cancer globally, we aimed to understand the extent of posts regarding this disease on Instagram, one of the most used social media platforms.

**Methodology** We collected and analysed the number of Instagram posts for the following hashtags: #uterinecancer, #endometrialcancer, and #wombcancer from the launch of Instagram (October 2010) to May 5th, 2023. Moreover, using the Instagram algorithm, we highlighted the two top posts for each used hashtag.

**Results** We identified 83,670 posts related to endometrial cancer. More specifically, 48,597 posts for #uterinecancer, 28,234 posts for #endometrialcancer and 6,839 posts for #wombcancer. The most rated post on endometrial cancer belonged to a scientific research alliance providing an informative description of the disease, whereas the second top post consisted of a cancer-related nutritional advices advertisement for patients. Figure 1 summarises the most frequent words gathered from the top post comments. It shows that endometrial cancer posts are usually linked to everyday life factors according to patients’ point of view: hormonal changes, stressful life, hormonal therapy, and childbearing.

**Abstract #183 Figure 1** The word cloud of the top ranked post on endometrial cancer

**Conclusion** In conclusion, Instagram may be considered a crucial social media platform for patients with endometrial cancer to obtain information regarding their disease.

**Disclosures** None

---

**#206 MALIGNANT MIXED MULLERIAN TUMOUR OF THE UTERUS: ANALYSIS OF 80 CASES FROM A SINGLE ACADEMIC INSTITUTION**

**Introduction/Background** The aim of our study was to evaluate the clinicopathological features and prognostic factors of uterine mixed muller malignant tumor (MMMT).

**Methodology** In this retrospective study, the clinical characteristics patients with uterine MMMT were evaluated. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank est.

**Results** Eighty patients with uterine carcinosarcoma were referred at University of Bari between 1995 and 2022. Their median age was 66.5 years. All women underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty-five percent had also omental resection. Pelvic lymphadenectomy was performed in 18% of the cases. The distribution by FIGO stage showed 21% in stage I (8% in stage IA and 13% in stage in stage IB), 35% in stage II, 35% in stage III and 9% in stage IV. Adjuvant chemotherapy was administered to 54 patients (67%). Disease recurrence was observed in 26 cases (32%). The disease-free interval, defined as the time interval between the end of the first line of chemotherapy and the appearance of recurrence or distant metastases, was 23 months. The median overall survival was 103 months.

The evaluation of survival according to FIGO stage, histological type, tumour size, chemotheraphy regimen, pelvic lymphadenectomy, and myometrial invasion provided results not statistically significant for prognostic purposes. However, no statistical differences were observed after adjusting for FIGO stage. Only tumour histotype was found to be a decisive element for prognostic evaluation after adjusting for stage: patients with homologous-type MMMT demonstrated a survival advantage in an advanced stage compared to an early stage.

**Conclusion** Uterine MMMT is an aggressive tumour, often diagnosed at an advanced stage and with a high rate of metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.

**Disclosures** None

---

**#207 THE ROLE OF HISTOLOGICAL AND MOLECULAR FEATURES IN PREDICTING THE RISK OF NODAL DISEASE IN ENDOMETRIAL CANCER: A PROSPECTIVE STUDY**

**Introduction/Background** To assess the role of histopathological and molecular features in predicting the risk of nodal metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.

**Disclosures** None